{"id":"NCT04123548","sponsor":"Stratatech, a Mallinckrodt Company","briefTitle":"StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )","officialTitle":"A Multicenter, Open-label, Study of StrataGraft® Skin Tissue in Adult Subjects With Deep Partial-Thickness Thermal Burns","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-18","primaryCompletion":"2022-01-26","completion":"2022-01-26","firstPosted":"2019-10-11","resultsPosted":"2023-11-09","lastUpdate":"2023-11-09"},"enrollment":52,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Deep Partial-thickness Burn"],"interventions":[{"type":"BIOLOGICAL","name":"StrataGraft skin tissue","otherNames":["Experimental skin tissue"]}],"arms":[{"label":"StrataGraft","type":"EXPERIMENTAL"}],"summary":"An autograft is a piece of skin taken from a healthy area of the body to be used to treat severe burns on another part of the same body.\n\nStrataGraft skin tissue was an investigational tissue that could be used as an alternative to an autograft.\n\n* StrataGraft skin tissue was in late-stage clinical development for the treatment of adults with deep partial-thickness (DPT) burns.\n* There were no safety concerns reported to date. The sponsor submitted a treatment protocol to Food and Drug Administration (FDA) for doctors who participated in the Phase 3 Strata 2016 study (NCT 03005106) to allow for expanded access to StrataGraft before it was commercially available.\n\nThe main purpose of the study was to allow patients to receive StrataGraft during Biologics License Application review and prior to approval by the FDA for the treatment of DPT burns. The primary outcome measure was the number of participants with adverse events and safety concerns.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"AEs were collected on each individual participant for the duration of their study participation, i.e. from the time of signing the informed consent until study completion (up to approximately 7 months).","effectByArm":[{"arm":"StrataGraft","deltaMin":46,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["39043513"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":52},"commonTop":["Pruritus","Pain","Constipation","Neuralgia","Blister"]}}